Side by side
Cagrilintide vs Tesamorelin
Both are discussed for weight loss. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| Cagrilintide | Tesamorelin | |
|---|---|---|
| What it is | A long-acting amylin analogue in late-stage trials. It works on a different satiety pathway from the GLP-1 drugs. Which is why it is being developed alongside semaglutide rather than against it. | A GHRH analogue approved by the FDA for reducing excess visceral fat in HIV-associated lipodystrophy. The only compound in this category with completed phase 3 trials. |
| EvidenceHow much human evidence exists, not how well it works. | Clinical trials | Approved for another indication |
| Regulatory statusReviewed 2026-08-16 | Not approved anywhere, alone or in combination. In late-stage clinical development as CagriSema, a fixed combination with semaglutide. Anything sold as cagrilintide today is a research chemical produced outside the manufacturing controls that a future approval would rest on. | Approved by the FDA as a prescription medicine for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for body composition, athletic performance or anti-ageing use, and material sold as a research chemical is not the approved product. |
| Routes | Subcutaneous | Subcutaneous |
| Half-life | 180 hours | 0.4 hours |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $4.40/mg | $2.35/mg |
| Median per mg | $9.60/mg | $7.00/mg |
| Vendors with a price | 31 | 49 |
| Storage once mixed | Refrigerated at 2–8 °C. Do not freeze once mixed. | Refrigerated at 2–8 °C. The approved product is intended for use shortly after reconstitution rather than stored for weeks. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.